Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

Are opinions changing on changing therapies in MS?

October 22, 2019

…7-323). Relapses were most often evaluated every six months, and MRIs were commonly obtained annually in the first few years of treatment. No evidence of disease activity (NEDA) was not considered to be an achievable or sustainable goal, which reflected the findings from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital (CLIMB) cohort study (Rotstein et al. JAMA Neurol 2015;72:152-158). As a consequ…

Are opinions changing on changing therapies in MS?

October 22, 2019

…7-323). Relapses were most often evaluated every six months, and MRIs were commonly obtained annually in the first few years of treatment. No evidence of disease activity (NEDA) was not considered to be an achievable or sustainable goal, which reflected the findings from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital (CLIMB) cohort study (Rotstein et al. JAMA Neurol 2015;72:152-158). As a consequ…

Report on higher-efficacy therapies in MS – ECTRIMS 2019

October 2, 2019

…019; abstract P1017). At >6 months after switching, 91.5% remained relapse-free. Similar benefits were seen in TREAT-MS, an ongoing real-world study of alemtuzumab (Ziemssen et al. ECTRIMS 2019; abstract P988). In the subgroup of patients previously treated with >3 prior DMTs, 73.1% were relapse-free, ARR decreased from 1.7 to 0.24, and EDSS scores were unchanged (mean -0.1) in the two years after switching. Survey – Report on higher-efficacy ther…

ECTRIMS 2019 SLIDE DECK

September 26, 2019

…required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire Download available on Google Chrome, Internet Explorer, Safari, Firefox and Edge. Should you experience technical difficulties in downloading the PowerPoint file, please email us:at i…

ECTRIMS 2019 DAILY REPORT – SATURDAY EDITION

September 14, 2019

…continuous DMF 240 mg BID for 10 years reported that 51% remained relapse-free (Gold et al. ECTRIMS 2019; abstract P1397). The median time to first relapse was 9.7 years. A total of 79% had minimal disability (EDSS score < 3.5) at 10 years, with 64% demonstrating no confirmed disability progression from baseline. The incidence of serious infections was 2% in Year 1 and < 1% every year thereafter. Back to top Declining effect of treatment An MSBas…